DE60134575D1 - Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator - Google Patents

Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator

Info

Publication number
DE60134575D1
DE60134575D1 DE60134575T DE60134575T DE60134575D1 DE 60134575 D1 DE60134575 D1 DE 60134575D1 DE 60134575 T DE60134575 T DE 60134575T DE 60134575 T DE60134575 T DE 60134575T DE 60134575 D1 DE60134575 D1 DE 60134575D1
Authority
DE
Germany
Prior art keywords
insulinsekretion
sensibilizer
insulin
amplifier
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60134575T
Other languages
English (en)
Inventor
Malcolm Allison
Marjorie Regan Gatlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Pharma GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24581689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60134575(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma GmbH, Novartis AG filed Critical Novartis Pharma GmbH
Application granted granted Critical
Publication of DE60134575D1 publication Critical patent/DE60134575D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60134575T 2000-08-22 2001-08-20 Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator Expired - Lifetime DE60134575D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64364100A 2000-08-22 2000-08-22
PCT/EP2001/009587 WO2002015933A2 (en) 2000-08-22 2001-08-20 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser

Publications (1)

Publication Number Publication Date
DE60134575D1 true DE60134575D1 (de) 2008-08-07

Family

ID=24581689

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60134575T Expired - Lifetime DE60134575D1 (de) 2000-08-22 2001-08-20 Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator

Country Status (15)

Country Link
US (1) US20040034065A1 (de)
EP (3) EP1351683B1 (de)
JP (4) JP2004514654A (de)
AR (1) AR033390A1 (de)
AT (1) ATE399010T1 (de)
AU (1) AU2001287698A1 (de)
CL (1) CL2009001899A1 (de)
CY (1) CY1111698T1 (de)
DE (1) DE60134575D1 (de)
DK (1) DK1351683T3 (de)
MY (1) MY141012A (de)
PE (1) PE20020617A1 (de)
PT (1) PT1351683E (de)
TW (3) TWI327469B (de)
WO (1) WO2002015933A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
CA2478599A1 (en) * 2002-03-11 2003-09-18 Novartis Ag Salts of nateglinide
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US7582662B2 (en) * 2002-12-27 2009-09-01 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
ES2535291T3 (es) * 2003-04-15 2015-05-08 Daiichi Sankyo Company, Limited Medoxomilo de olmesartán para prevención o tratamiento de enfermedades oculares angiogénicas
EP1631556A1 (de) * 2003-05-16 2006-03-08 Novartis AG Pharmazeutische zusammensetzung enthaltend valsartan
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
AU2005243214B2 (en) 2004-04-29 2011-07-07 U.S. Smokeless Tobacco Company Llc Nicotiana nucleic acid molecules and uses thereof
US7666899B2 (en) * 2004-05-11 2010-02-23 Kissei Pharmaceutical, Co. Ltd. Pharmaceutical composition for treatment of lipid metabolism disorder
WO2005117591A2 (en) * 2004-05-28 2005-12-15 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
UY29155A1 (es) * 2004-10-07 2006-02-24 Takeda Pharmaceutical Un agente para la profilaxis o tratamietno del sindrome metabolico
JP2007099764A (ja) * 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
WO2010122927A1 (ja) * 2009-04-20 2010-10-28 第一三共株式会社 糖尿病由来神経再生遅延の予防又は治療のための医薬

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0403159B1 (de) 1989-06-14 2000-03-01 Smithkline Beecham Corporation Imidazoalkensäure
EP0512042B1 (de) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1-analoga verwendbar in der diabetesbehandlung
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
JP2921982B2 (ja) 1991-06-21 1999-07-19 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｓ）（＋）−２−エトキシ−４−［ｎ−［１−（２−ピペリジノ−フェニル）−３−メチル−１−ブチル〕アミノカルボニルメチル〕−安息香酸、この化合物を含む医薬組成物及びその調製方法
DE69217762T2 (de) 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
TW226375B (de) 1991-10-24 1994-07-11 American Home Prod
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2184712A1 (en) * 1994-03-17 1995-09-21 Marc De Gasparo Treatment of diabetic nephropathy with valsartan
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
US5488510A (en) 1994-07-26 1996-01-30 Lemay; Edward J. Enhanced depth perception viewing device for television
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU713277B2 (en) * 1996-04-05 1999-11-25 Takeda Pharmaceutical Company Limited Pharmaceutical combination containing a compound having angiotensin II and antagonistic activity
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
US6251926B1 (en) * 1998-05-11 2001-06-26 Takeda Chemical Industries, Ltd. Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
DE69936992T2 (de) * 1998-07-10 2008-03-06 Novartis Pharma Ag Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
ES2246894T3 (es) * 1999-08-30 2006-03-01 Sanofi-Aventis Deutschland Gmbh Ramipril para la prevencion de sucesos cardiovasculares.
TW200528436A (en) * 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20020037829A1 (en) * 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents

Also Published As

Publication number Publication date
ATE399010T1 (de) 2008-07-15
DK1351683T3 (da) 2008-10-20
TWI327469B (en) 2010-07-21
WO2002015933A2 (en) 2002-02-28
EP2138175A2 (de) 2009-12-30
TWI327468B (en) 2010-07-21
EP1980249A2 (de) 2008-10-15
AR033390A1 (es) 2003-12-17
TW200838503A (en) 2008-10-01
US20040034065A1 (en) 2004-02-19
EP2138175A3 (de) 2010-01-13
WO2002015933A3 (en) 2003-08-14
EP1351683B1 (de) 2008-06-25
TW200843741A (en) 2008-11-16
CY1111698T1 (el) 2015-10-07
MY141012A (en) 2010-02-25
AU2001287698A1 (en) 2002-03-04
EP1980249A3 (de) 2010-04-28
JP2004514654A (ja) 2004-05-20
EP1351683A2 (de) 2003-10-15
JP2015205909A (ja) 2015-11-19
JP2010043101A (ja) 2010-02-25
CL2009001899A1 (es) 2010-02-12
PT1351683E (pt) 2008-09-18
TWI315197B (en) 2009-10-01
JP2013049683A (ja) 2013-03-14
PE20020617A1 (es) 2002-08-05

Similar Documents

Publication Publication Date Title
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
ATE430145T1 (de) 3-ä(2-ä 4-(hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü -propionsäure- ethylester -methansulfonat und dessen verwendung als arzneimittel
DE60324099D1 (de) Arzneistoffhaltiger tampon
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ATE277910T1 (de) Urazil verbindungen und deren verwendung
DE50112013D1 (de) Deodorantien und antiperspirantien
PT1307457E (pt) Compostos heterociclicos sua preparacao e utilizacao como medicamentos noemadamente como antibacterianos
DE60326611D1 (de) N und dergleichen
DE60106423D1 (de) Entzündungshemmende verbindungen und ihre verwendung
NO20055246D0 (no) Heteroaromatisk pentasyklisk forbindelse og medisinsk anvendelse derav
DE60230583D1 (de) Spielvorrichtung und Spielprogramm
EP1541585A4 (de) Cxcr4-antagonist und dessen verwendung
DE60138102D1 (de) Antikörper gegen menschliches mcp-1
DE60134575D1 (de) Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator
DE50010609D1 (de) Sport-trainings-vorrichtung sowie sport-trainings-system
ATE423117T1 (de) Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone
ATE399542T1 (de) Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
ATE419248T1 (de) Phenylsubstituierte 4-hydroxy-tetrahydropyridone und ihre verwendung als schädlingsbekämpungsmittel und herbizide
DE60318139D1 (de) Isolator- und Anordnungskonfiguration
DE50105970D1 (de) Verstemmstempel und verwendung desselben
DE50108402D1 (de) N-alkoxyalkyl-substituierte benzimidazole und ihre verwendung als mittel gegen parasitäre protozoen
FI20031927A0 (fi) Terapeuttisesti vaikuttavia aineita ja niiden käyttö
ATE347544T1 (de) Substituierte phenylcyclohexancarbonsäureamide und ihre verwendung
FR2847430B1 (fr) Cendrier jetable et portable

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN